Show simple item record

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.

dc.contributor.authorSteele, N
dc.contributor.authorAnthony, A
dc.contributor.authorSaunders, Mark P
dc.contributor.authorEsmarck, B
dc.contributor.authorEhrnrooth, E
dc.contributor.authorKristjansen, P
dc.contributor.authorNihlén, A
dc.contributor.authorHansen, L
dc.contributor.authorCassidy, J
dc.date.accessioned2012-06-22T10:06:22Z
dc.date.available2012-06-22T10:06:22Z
dc.date.issued2012-02-28
dc.identifier.citationA phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. 2012, 106 (5):793-8 Br J Canceren_GB
dc.identifier.issn1532-1827
dc.identifier.pmid22315057
dc.identifier.doi10.1038/bjc.2011.599
dc.identifier.urihttp://hdl.handle.net/10541/230191
dc.description.abstractPre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor. This phase 1 trial assessed the safety and tolerability of escalating doses of rIL-21 in combination with cetuximab in chemo-naïve patients with stage IV colorectal cancer.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren_GB
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshColorectal Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInterleukins
dc.subject.meshMale
dc.subject.meshMaximum Tolerated Dose
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshTreatment Outcome
dc.titleA phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK. n.steele@nhs.neten_GB
dc.identifier.journalBritish Journal of Canceren_GB
html.description.abstractPre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor. This phase 1 trial assessed the safety and tolerability of escalating doses of rIL-21 in combination with cetuximab in chemo-naïve patients with stage IV colorectal cancer.


This item appears in the following Collection(s)

Show simple item record